Thursday, July 28, 2016 3:42:28 PM
American Capital
Originally issued:
Stock: 750,000 shares
Series A: 750,000
Series B: 1,500,000
Series C: 1,500,000
Series D: 750,000
Series E: 750,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000114420415016463/v404523_sc13g.htm
Stock: 1,500,000 shares
Series A: 750,000
Series B: 0
Series C: 1,500,000
Series D: 750,000
Series E: 750,000
Iroquois Capital Management
Originally Issued:
Stock: 1,250,000 shares
Series A: 1,250,000
Series B: 2,500,000
Series C: 2,500,000
Series D: 1,250,000
Series E: 1,250,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000093041316005298/c83897_sc13ga.htm
Stock: 2,231,124 shares
Series A: 1,250,000
Series B: 0
Series C: 2,500,000
Series D: 1,250,000
Series E: 1,250,000
Abbe Trusts
Originally Issued:
Stock: 499,995 shares
Series A: 499,995
Series B: 999,990
Series C: 999,990
Series D: 499,995
Series E: 499,995
This is what they currently claim to own on Iroquois’ most current 13G/A under Richard Abbe Sole power: http://www.sec.gov/Archives/edgar/data/1094038/000093041316005298/c83897_sc13ga.htm
Stock: 499,995 shares
Series A: 250,000
Series B: 0
Series C: 499,995
Series D: 499,995
Series E: 499,995
OK, here comes the cloudy part. The following two entities do not claim to have any Series A, D, or E warrants on their most recent 13G/A filings. I have decided to assume that they exercised their A warrants and still hold their D & E warrants as these are currently not at exercise price. The price was in range of the D warrants but since they have not exercised enough C warrants they therefore cannot exercise any D warrants. Like I said in the beginning the math will eventually make sense.
Empery Asset Management
Originally Issued:
Stock: 2,320,000 shares
Series A: 2,320,000
Series B: 4,640,000
Series C: 4,640,000
Series D: 2,320,000
Series E: 2,320,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000090266416004887/p16-0110sc13ga.htm
Stock: 757,000 shares
Series A: 0
Series B: 0
Series C: 2,320,000
Series D: 2,320,000
Series E: 2,320,000
Brio Capital Master Fund
Originally Issued:
Stock: 2,500,000 shares
Series A: 2,500,000
Series B: 5,000,000
Series C: 5,000,000
Series D: 2,500,000
Series E: 2,500,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000121390016010454/sc13g0116a1briocapital_tapim.htm
Stock: 0 shares
Series A: 0
Series B: 0
Series C: 4,711,239
Series D: 2,320,000
Series E: 2,320,000
Recent MRKR News
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 11:22:44 AM
- Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program • GlobeNewswire Inc. • 08/07/2023 11:00:17 AM
- Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023 • GlobeNewswire Inc. • 07/26/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 11:09:50 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM